Project Grant R43AI188659
Award Date 9/2/26
Completion Date 8/31/28
Dollars Obligated $307K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Washington, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Kinvard Bio, Inc. $314,363 on August 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop oxepanoprolinamide antibiotics for the treatment of complicated urinary tract infections. Kinvard Bio is conducting microbiological profiling of oxepanoprolinamide (OPP) candidates, a new class of ribosome-binding antibiotics designed to treat gram-negative infections resistant to standard-of-care...
- The National Institute of Allergy and Infectious Diseases awarded Wake Forest University Health Sciences $198,798 on August 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop monoclonal antibodies against disseminating Klebsiella pneumoniae. The project addresses antibiotic-resistant Klebsiella pneumoniae infections that translocate from the gastrointestinal tract into the bloodstream, causing systemic infections including bacteremia, liver abscesses,...
- The National Institute of Allergy and Infectious Diseases awarded The Broad Institute, Inc. $480,650 on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a genome-wide association study identifying genetic determinants of carbapenem resistance in Klebsiella pneumoniae. The project addresses knowledge gaps in understanding resistance mechanisms in carbapenem-resistant K. pneumoniae strains. The recipient will perform a reference-free GWAS using...
- The National Institute of Allergy and Infectious Diseases awarded The Research Foundation For The State University Of New York $799,743 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop novel dual-acting therapeutics against multidrug-resistant and hypervirulent Klebsiella pneumoniae strains. The project targets the development of first-in-class, dual-acting anti-virulence antibiotics that address a critical gap in current treatment...
- The National Institute of Allergy and Infectious Diseases awarded the University of Pittsburgh $412,942 on February 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how host-derived environmental signals in the gastrointestinal tract regulate hypervirulent Klebsiella pneumoniae virulence gene expression and capsule production during intestinal colonization and systemic dissemination. The research employs RNA sequencing and genetic approaches to...
- The National Institute of Allergy and Infectious Diseases awarded the University of Pennsylvania $785,766 on July 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Project Grant R01AI202932) to quantify respiratory and gut bacterial strain persistence and predict pneumonia treatment failure. The recipient will develop a prospective human-subjects cohort called REBEL (Respiratory Bacterial Load) to characterize bacterial load dynamics during and after...
- The National Institute of Allergy and Infectious Diseases awarded Drexel University $554,786 on September 17, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to fund basic research on mechanisms by which the probiotic Lactobacillus rhamnosus (LGG) modulates antimicrobial peptide signaling and innate immune response to influenza virus in neonates. The project, titled "Use of Probiotics to Modulate Antimicrobial Peptide Signaling in the Neonatal Innate Immune...
- The National Institute of Allergy and Infectious Diseases awarded The Children's Hospital of Philadelphia $448,292 on July 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of ceftazidime-avibactam in combination with meropenem in the prevention and treatment of mutant KPC-producing infections using a hollow fiber infection model. KPC-producing Enterobacterales infections carry mortality rates upwards of 40 percent....
- The National Institute of Allergy and Infectious Diseases awarded $1.5 million to The Washington University on June 24, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop antibiotic-sparing strategies for treatment of bacterial infections caused by multidrug-resistant pathogens including carbapenem-resistant Enterobacterales, ESBL-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, multidrug-resistant Pseudomonas aeruginosa,...
- The National Institute of Allergy and Infectious Diseases awarded The Trustees of Columbia University in the City of New York $452,375 on June 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify transcription factors that promote pulmonary infection by opportunistic pathogens. The recipient will conduct research to determine how the transcription factor RpoN responds to environmental signals in Pseudomonas aeruginosa and Klebsiella pneumoniae, and how...